Skip to main content
. 2012 Nov 28;54(1):1–14. doi: 10.3349/ymj.2013.54.1.1

Fig. 2.

Fig. 2

EGFR-TKI is effective in patients with distinct clinico-pathological and pharmacogenomical features. EGFR, epidermal growth factor receptor; TKI, tyrosine-kinase inhibitor; BAC, bronchial alveolar cell; FISH, fluorescence in situ hybrydization.